ERBB2 and breast cancer: The GeparOcto trial, which included luminal B subtypes only if lymph node positive, failed to show a proposed pCR difference of 10% assuming a pCR rate of 50% in the control group [28], and the GENEVIEVE trial was close to succeed in showing a proposed 10% (1.2 versus 10.8%) pCR improvement for TNBC or ER-positive/HER2-negative BC [29].